利培酮合并氯氮平治疗难治性精神分裂症的对照研究

目的探讨利培酮合并氯氮平治疗难治性精神分裂症的疗效及副作用.方法将101例难治患者用配对半随机法分成利培酮组（A）、氯氮平组（B）及二药联用组（AB），疗期8周，用PANSS、CGI、TESS评定疗效及副作用.结果三组8周疗效相似（p>0.05），有效率A组60.0％、B组61.8％、AB组62.5%；AB组与A组均于第一周起效，治疗2周时AB组疗效较单用组佳（p<0.05），对阳性症状疗效突出（p<0.05）；AB组副作用比单用组少.结论利培酮与氯氮平治疗难治性精神分裂症有效，二药联用对某些难治病例更安全有效.

A Control Study of Risperidone in Combination with Clozapine in Treating Refractory Schizophrenia

Objective To explore the efficacy and side effects of the combination therapy of risperidone and clozapine on refractory schizophrenia.Methods 101 cases with refractory schizophrenia matched in duration and types of disease were randomly divided into three groups (A, B and AB ) and treated with risperidone,clozapine and combined therapy respectively for 8 weeks. The efficacy and side effects were assessed with PANSS, CGI and TESS.Results There was no significant efficacy difference (p>0.05) among group AB(62.5%), group A(60.0%) and group B(61.8%) after 8 weeks treatment. Both group AB and group A responded at the first week, and the efficacy of group AB was superior to that of the other two groups (p<0.05) after 2 weeks, especially for positive symptoms(p<0.05). There were fewer side effects in group AB than the other two groups.Conclusions Risperidone was a effective treatment for refractory schizophrenia as well as Clozapine, and it could be a more safe and effective treatment if two drugs were used in combination.